Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hematopoietic Cell Transplantation for Myelodysplastic Syndromes.

Journal of oncology practice - 1 Sept 2016

Bhatt Vijaya Raj, Steensma David P

Abstract excerpt

Allogeneic hematopoietic cell transplantation (HCT) offers the only potential cure for patients with myelodysplastic syndromes (MDS). However, with current approaches to HCT, many older patients with comorbidities are poor HCT candidates, and treatment-related morbidity and mortality may offset benefit for patients with lower-risk disease. Consequently, selection of patients with MDS for HCT should take into...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Hematologic Neoplasms
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myelodysplastic Syndromes

Share to Neoplasm Recurrence, Local

Share to Prognosis

Share to Tissue Donors

Share to Transplantation Conditioning

Source

Identifiers

PMID: 27621329
DOI: 10.1200/JOP.2016.015214

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hematopoietic Cell Transplantation for Myelodysplastic Syndromes.PMID 27621329Read ↗

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review.Semantic proximity Read ↗

Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic SyndromesSemantic proximity Read ↗

Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation.Semantic proximity Read ↗

The current and future role of stem cells in myelodysplastic syndrome therapies.Semantic proximity Read ↗

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.Semantic proximity Read ↗

Current therapeutic approaches for patients with myelodysplastic syndromes.Semantic proximity Read ↗

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.Semantic proximity Read ↗

TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.Semantic proximity Read ↗

Hemopoietic cell transplantation for the myelodysplastic syndromes.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.Semantic proximity Read ↗

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.